factor
viii
fviii
concentr
revolution
treatment
patient
haemophilia
concern
transmiss
viral
infect
product
address
stringent
donorscreen
procedur
robust
antivir
manufactur
step
bio
product
laboratori
develop
highpur
fviii
product
von
willebrand
factor
optiv
safeti
toler
efficaci
prophylaxi
treatment
bleed
establish
longterm
studi
seventi
previous
treat
patient
sever
haemophilia
exposur
day
recruit
two
longterm
multicentr
openlabel
studi
protocol
virtual
ident
patient
receiv
optiv
either
prophylact
ondemand
mean
ed
experienc
infus
condit
optiv
well
toler
patient
experienc
treatmentrel
advers
event
commonli
report
headach
patient
dizzi
patient
mean
number
bleedspati
year
treatment
period
prophylact
use
ondemand
use
patient
treat
prophylact
clinic
respons
breakthrough
bleed
rate
physician
excel
good
help
help
patient
bleed
clinic
respons
ondemand
patient
rate
excel
good
physician
help
help
patient
bleed
viral
transmiss
inhibitor
studi
confirm
clinic
efficaci
safeti
optiv
prophylact
ondemand
manag
patient
haemophilia
well
known
factor
viii
fviii
concentr
revolution
treatment
patient
haemophilia
consider
improv
patient
qualiti
life
transmiss
hepat
hav
hepat
b
hbv
nonanonb
hepat
hiv
signific
setback
mani
prevent
measur
implement
reduc
risk
viral
transmiss
transfus
plasma
product
includ
donor
screen
virucid
procedur
viru
erad
step
manufactur
exampl
bio
product
laboratori
bpl
introduc
intermediatepur
fviiivon
willebrand
factor
vwf
concentr
manufactur
use
dri
heattreat
h
known
broad
antivir
effect
last
year
well
toler
treatment
haemophilia
von
willebrand
diseas
vwd
without
transmiss
hepat
hepat
b
hepat
c
hiv
low
incid
inhibitor
new
highpur
product
optiv
bio
product
laboratori
elstre
uk
develop
includ
novel
chromatograph
purif
step
remov
unnecessari
protein
fibrinogen
fibronectin
addit
specif
wellestablish
solventdeterg
step
includ
minim
transmiss
envelop
virus
includ
west
nile
dri
heat
h
process
use
known
inactiv
sar
viru
retain
two
specif
virucid
step
taken
manufactur
optiv
consid
effect
envelop
nonenvelop
virus
eg
hav
parvoviru
normal
pharmacokinet
optiv
report
elsewher
patient
haemophilia
patient
vwd
nowaday
develop
inhibitor
antibodi
remain
concern
new
fviii
product
late
earli
two
outbreak
inhibitor
amongst
previous
treat
patient
ptp
treat
new
concentr
show
chang
manufactur
process
could
result
format
neoantigen
lead
inhibitor
format
sinc
essenti
evalu
new
fviii
concentr
ptp
establish
whether
unusu
antigen
paper
report
consolid
clinic
data
collect
prospect
followup
period
year
two
studi
conduct
assess
safeti
efficaci
optiv
patient
sever
haemophilia
two
studi
call
pharmacokinet
pk
safeti
efficaci
se
conduct
design
virtual
ident
longterm
clinic
data
combin
report
major
differ
studi
one
pk
addit
provid
pharmacokinet
profil
patient
previou
fviii
optiv
pk
data
report
elsewher
studi
multicentr
intern
openlabel
nonrandom
prospect
studi
compliant
guidelin
issu
committe
proprietari
medicin
product
cpmp
known
committe
medicin
product
human
use
chmp
ethic
committe
approv
written
inform
consent
obtain
clinic
assess
visit
schedul
ident
studi
prestudi
screen
week
prior
optiv
given
firstdos
assess
follow
month
home
therapi
seconddos
assess
end
period
follow
month
home
therapi
regular
followup
phone
throughout
review
haemophilia
centr
patient
elig
inclus
male
year
old
haemophilia
basal
fviii
activ
time
diagnosi
without
inhibitor
least
exposur
day
ed
se
studi
exclus
criteria
histori
inhibitor
intern
normal
ratio
thrombocytopenia
platelet
l
clinic
signific
renal
diseas
creatinin
lmol
l
clinic
signific
liver
diseas
alanin
transaminas
level
three
time
upper
normal
limit
particip
anoth
clinic
trial
within
day
studi
entri
se
studi
patient
need
lymphocyt
count
l
patient
recruit
haemophilia
centr
poland
uk
optiv
use
prophylact
ondemand
accord
prefer
specif
medic
prohibit
studi
except
fviii
product
safeti
assess
monitor
viral
marker
antiparvoviru
hiv
hbv
hcv
hav
specifi
time
fviii
inhibitor
screen
monthli
routin
biochemistri
haematolog
advers
event
ae
fviii
inhibitor
screen
perform
use
standard
activ
partial
thromboplastin
time
incub
techniqu
recommend
uk
haemophilia
centr
doctor
organ
ukhcdo
screen
test
posit
bethesda
nijmegen
quantit
assay
perform
extent
exposur
also
determin
efficaci
assess
number
type
sever
bleed
new
bleed
breakthrough
bleed
ongo
bleed
bleed
requir
addit
optiv
dose
subject
assess
haemostasi
made
clinician
patient
sampl
size
chosen
studi
excess
prescrib
chmp
guidanc
descript
statist
present
subdivid
prophylact
ondemand
use
modal
treatment
random
formal
compar
statist
test
use
prophylaxi
defin
least
two
prophylact
dose
per
week
total
patient
enrol
pk
studi
se
studi
except
one
africancaribbean
patient
caucasian
patient
treat
prophylact
ondemand
fig
ondemand
patient
administ
intermitt
prophylact
dose
mostli
increas
physic
activ
consolid
baselin
demograph
particip
shown
tabl
durat
infus
patient
receiv
optiv
mean
period
week
tabl
signific
differ
mean
durat
treatment
per
patient
two
optiv
usag
group
week
prophylact
group
week
ondemand
group
overal
experi
studi
patientyear
altogeth
infus
optiv
use
studi
record
mean
ed
tabl
includ
patient
prophylaxi
dose
prophylact
infus
treat
bleed
ondemand
use
infus
treat
bleed
dose
intermitt
prophylaxi
tabl
overal
mean
number
infus
administ
per
patient
polish
subject
fewer
ed
per
patient
uk
patient
tabl
dose
optiv
bleed
occur
patient
prophylaxi
mean
dosepati
use
new
bleed
iu
kg
mean
total
ongo
bleed
iu
kg
per
patient
comparison
ondemand
patient
use
slightli
lower
dose
new
ongo
bleed
tabl
addit
patient
prophylact
group
ondemand
patient
administ
intermitt
prophylact
dose
overal
mean
prophylact
dose
iu
kg
per
patient
iu
kg
prophylact
group
iu
kg
intermitt
prophylaxi
ondemand
group
tabl
patient
uk
use
higher
prophylact
dose
per
infus
poland
administ
frequent
prophylact
dose
prophylact
dose
per
week
per
patient
respect
tabl
tabl
overal
bleed
joint
muscl
bleed
openoth
bleed
remain
locat
specifi
tabl
object
outcom
bleed
episod
assess
clinician
bleed
bleed
patient
patient
treat
prophylact
clinician
rate
optiv
therapi
excel
good
assess
bleed
episod
patient
report
clinic
respons
help
help
control
bleed
episod
assess
bleed
prophylact
group
ondemand
group
tabl
consolid
ae
prophylact
group
one
patient
report
five
treatmentrel
ae
tabl
exposur
day
optiv
prophylact
ondemand
subgroup
prophylact
subgroup
n
ondemand
subgroup
n
overal
n
ci
confid
interv
exposur
day
day
patient
receiv
least
one
infus
whether
administ
prophylaxi
ondemand
bleed
includ
bolu
dose
recoveri
assess
bleed
locat
specifi
aim
studi
evalu
fviii
vwf
concentr
optiv
ptp
although
data
origin
formal
clinic
studi
outcom
repres
usual
clinic
practic
exampl
dose
given
nearest
whole
iu
vial
combin
safeti
efficaci
data
two
similar
studi
optiv
includ
report
studi
use
optiv
analys
prophylact
use
ondemand
use
patient
random
comparison
appropri
howev
standard
manag
patient
sever
haemophilia
involv
either
one
treatment
modal
therefor
inclus
treatment
regimen
studi
allow
clinic
util
optiv
establish
comprehens
patient
use
optiv
prophylact
differ
age
use
ondemand
although
minor
use
prophylact
overal
ondemand
patient
tend
use
lower
dose
prophylact
group
treat
bleed
intermitt
prophylaxi
patient
use
optiv
prophylact
experienc
third
number
bleed
ondemand
bleed
rate
bleed
per
week
per
patient
bleed
per
week
per
patient
respect
outcom
accord
two
treatment
modal
compar
expect
major
polish
patient
treat
ondemand
consum
less
fviii
product
compar
treat
uk
efficaci
optiv
explor
qualit
assess
impact
prophylact
ondemand
treatment
subject
outcom
spontan
bleed
physicianand
patientbas
assess
respons
yield
similar
posit
result
data
collect
spontan
bleed
provid
evid
efficaci
optiv
rel
fviii
product
compar
studi
result
studi
howev
indic
prophylact
use
optiv
effect
fewer
bleed
ondemand
use
use
optiv
well
toler
patient
safeti
concern
use
optiv
either
prophylact
ondemand
seven
patient
experienc
treatmentrel
ae
time
longterm
followup
number
ae
report
unusu
high
type
ae
compar
highpur
product
commonli
report
treatmentrel
ae
headach
dizzi
treatmentrel
ae
experienc
treatment
group
headach
format
inhibitor
current
repres
major
obstacl
success
treatment
patient
haemophilia
absenc
inhibitor
trial
optiv
support
use
clinic
practic
although
patient
ptp
vwf
content
optiv
may
contribut
outcom
find
confirm
clinic
safeti
efficaci
optiv
prophylact
manag
ondemand
treatment
bleed
patient
sever
haemophilia
furthermor
concern
emerg
regard
fviii
inhibitor
articl
present
data
clinic
trial
fund
bio
product
laboratori
bpl
dr
clive
dash
work
consult
medic
director
bpl
rukhsana
shaikhzaidi
contract
bpl
work
clinic
research
consult
dr
ernest
gascoign
employe
bpl
three
author
potenti
conflict
interest
involv
prepar
articl
